These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Despite celiprolol therapy, patients with vascular Ehlers-Danlos syndrome remain at risk of vascular events: A 12-year experience in an Italian referral center. Buso G; Paini A; Agabiti-Rosei C; De Ciuceis C; Bertacchini F; Stassaldi D; Salvetti M; Ritelli M; Venturini M; Colombi M; Muiesan ML Vasc Med; 2024 Jun; 29(3):265-273. PubMed ID: 38102934 [TBL] [Abstract][Full Text] [Related]
3. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Ong KT; Perdu J; De Backer J; Bozec E; Collignon P; Emmerich J; Fauret AL; Fiessinger JN; Germain DP; Georgesco G; Hulot JS; De Paepe A; Plauchu H; Jeunemaitre X; Laurent S; Boutouyrie P Lancet; 2010 Oct; 376(9751):1476-84. PubMed ID: 20825986 [TBL] [Abstract][Full Text] [Related]
9. A multi-institutional experience in vascular Ehlers-Danlos syndrome diagnosis. Shalhub S; Byers PH; Hicks KL; Coleman DM; Davis FM; De Caridi G; Weaver KN; Miller EM; Schermerhorn ML; Shean K; Oderich G; Ribeiro M; Nishikawa C; Charlton-Ouw K; Behrendt CA; Debus ES; von Kodolitsch Y; Zarkowsky D; Powell RJ; Pepin M; Milewicz DM; Regalado ES; Lawrence PF; Woo K J Vasc Surg; 2020 Jan; 71(1):149-157. PubMed ID: 31353273 [TBL] [Abstract][Full Text] [Related]
10. Vascular Ehlers-Danlos Syndrome: A Comprehensive Natural History Study in a Dutch National Cohort of 142 Patients. Demirdas S; van den Bersselaar LM; Lechner R; Bos J; Alsters SIM; Baars MJH; Baas AF; Baysal Ö; van der Crabben SN; Dulfer E; Giesbertz NAA; Helderman-van den Enden ATJM; Hilhorst-Hofstee Y; Kempers MJE; Komdeur FL; Loeys B; Majoor-Krakauer D; Ockeloen CW; Overwater E; van Tintelen PJ; Voorendt M; de Waard V; Maugeri A; Brüggenwirth HT; van de Laar IMBH; Houweling AC Circ Genom Precis Med; 2024 Jun; 17(3):e003978. PubMed ID: 38623759 [TBL] [Abstract][Full Text] [Related]
12. Vascular Ehlers-Danlos Syndrome With a Novel Missense COL3A1 Mutation Present With Pulmonary Complications and Iliac Arterial Dissection. Gu G; Yang H; Cui L; Fu Y; Li F; Zhou Z; Zheng Y Vasc Endovascular Surg; 2018 Feb; 52(2):138-142. PubMed ID: 29216800 [TBL] [Abstract][Full Text] [Related]
19. Current Evidence and Future Perspectives in the Medical Management of Vascular Ehlers-Danlos Syndrome: Focus on Vascular Prevention. Buso G; Corvini F; Fusco EM; Messina M; Cherubini F; Laera N; Paini A; Salvetti M; De Ciuceis C; Ritelli M; Venturini M; Chiarelli N; Colombi M; Muiesan ML J Clin Med; 2024 Jul; 13(14):. PubMed ID: 39064294 [TBL] [Abstract][Full Text] [Related]
20. Spontaneous pneumothorax and hemothorax frequently precede the arterial and intestinal complications of vascular Ehlers-Danlos syndrome. Shalhub S; Neptune E; Sanchez DE; Dua A; Arellano N; McDonnell NB; Milewicz DM Am J Med Genet A; 2019 May; 179(5):797-802. PubMed ID: 30793832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]